GeneDx Holdings

GeneDx Holdings Total Assets

The Total Assets of GeneDx Holdings (WGS) as of Nov 15, 2026 is 523.71 M USD. In the previous year, Total Assets was 419.38 M USD — a change of 24.88% (higher).

Total Assets

523.71 MUSD

YoY

24.88%

Last updated:

Total Assets of GeneDx Holdings is 2025 523.71 M USD. Total Assets of GeneDx Holdings was 2024 419.38 M USD. It decreases by 24.88% higher compared to the previous year.

The GeneDx Holdings Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2020
251.64 M USD
Jan 1, 2021
554.09 M USD
Jan 1, 2022
545.26 M USD
Jan 1, 2023
418.76 M USD
Jan 1, 2024
419.38 M USD
Jan 1, 2025
523.71 M USD
The GeneDx Holdings Total Assets history
YEARTotal AssetsYoY
523.71 MUSD+24.88%
419.38 MUSD+0.15%
418.76 MUSD-23.20%
545.26 MUSD-1.59%
554.09 MUSD+120.19%
251.64 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneDx Holdings Stock analysis

What does GeneDx Holdings do? GeneDx Holdings Corp. generates revenue through its GeneDx and Legacy Sema4 segments. The GeneDx segment offers pediatric and rare disease diagnostics, primarily utilizing whole exome and genome sequencing, along with data and information services. It provides genetic diagnostic tests, screening solutions, and information to clinicians and patients. The Legacy Sema4 segment delivers reproductive and women’s health diagnostics, as well as somatic oncology testing and screening products. Both segments target healthcare providers and institutions seeking personalized health insights for diagnosis, treatment planning, and drug discovery. The company’s products include genetic diagnostic tests, screening solutions, and information services under the GeneDx brand, while Legacy Sema4 focuses on reproductive health, women’s health, and oncology diagnostics. These services are sold to healthcare providers and institutions that require actionable health intelligence to inform clinical decisions and improve patient outcomes. The segments serve distinct medical specialties, with GeneDx emphasizing rare diseases and pediatric care, and Legacy Sema4 covering reproductive health and cancer diagnostics. Revenue is derived from diagnostic testing services provided through both segments. The GeneDx segment’s core offerings are whole exome and genome sequencing for rare and pediatric conditions, while Legacy Sema4 specializes in reproductive, women’s health, and somatic oncology testing. These services are delivered to healthcare systems and providers who integrate genetic data into patient care pathways for better diagnosis and treatment strategies. GeneDx Holdings is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneDx Holdings stock

Total Assets of GeneDx Holdings is 523.71 M USD in 2025.

Total Assets of GeneDx Holdings changed from 419.38 M USD to 523.71 M USD, representing a 24.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets GeneDx Holdings since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's GeneDx Holdings historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — GeneDx Holdings

All Key Metrics — GeneDx Holdings